Last updated on May 2014

A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.


Brief description of study

A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.

Detailed Study Description

Patients with newly diagnosed or recurrent high risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor (TURBT) and received 3-6 instillations of intravesical treatment with BCG induction therapy will be enrolled in this two stage study.

Clinical Study Identifier: TX81670

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Debbie Johnson

First Urology, PSC
Jeffersonville, IN USA
  Connect »